News Releases

Date	Title and Summary	View
Sep 13, 2022	Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Sep 12, 2022	Johnson & Johnson Vision Launches New Contact Lens Innovation to Help Meet the Needs of Digitally Intense Lifestyles: ACUVUE® OASYS MAX 1-Day
Sep 08, 2022	TREMFYA®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Sep 06, 2022	Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology
Aug 27, 2022	Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Aug 24, 2022	U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
Aug 24, 2022	Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma
Aug 09, 2022	Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 04, 2022	European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Aug 02, 2022	Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference